We sought to develop a neurosurgical procedure to access the pons with a drug delivery device for chronic therapy and collect preliminary data on the toxicity of direct infusions of carboplatin in primates. METHODS: We made midline incisions on five cynomolgus monkeys, identified the inion, made a burr hole 2.5 cm below the inion, and inserted a catheter through the cerebellum into the roof of the pons. Pumps that infused saline for 90 days or carboplatin solutions for 30 to 35 days at 10 l/d were placed subcutaneously in the low cervical/high thoracic region. Monkeys were assessed by computed tomography and magnetic resonance imaging, laboratory studies, daily neurological observation, postmortem examinations, and histopathology. RESULTS: Monkeys infused with saline and 82 g of carboplatin remained neurologically intact throughout the infusion periods. Serial imaging showed that the catheter tip was in the pons and revealed no evidence of hemorrhage, edema, or migration. Two monkeys infused with up to 850 g of carboplatin showed hyperintense magnetic resonance imaging signals at Days 15 and 18 and neurological deficits at approximately Week 3. Platinum levels greater than 10 ng/mg tissue were detected over a distance of 1 cm in tissue slices. Histopathology demonstrated significant tissue necrosis around the tip of the catheter. CONCLUSION: The pons of monkeys is safely accessed with a catheter for drug delivery by using a posterior midline approach. Clinical observations, radiographic imaging, and laboratory tests of animals infused with saline for 3 months or 0.26 mg/ml of carboplatin for 1 month were unremarkable. Neurotoxicity was seen with dose levels of 2.6 mg/ml of drug for 1 month. This procedure offers opportunities for examining the toxicity of brainstem antitumor therapy in primates.
B
rainstem gliomas have historically been considered surgically inoperable, although magnetic resonance imaging (MRI) and stereotactic techniques have advanced the treatment of these lesions (20, 32) . Approximately 300 new cases are diagnosed yearly in the United States (36) ; about 70% of these cases are diffuse pontine gliomas (13) . Infiltrative tumors remain inoperable, rapidly progressive, and uniformly fatal (1, 26) . High levels of toxicity have frustrated researchers performing trials of systemic chemotherapy (14) . Because intratumoral (local) therapy decreases systemic toxicity, it is reasonable to investigate local therapy for these gliomas.
Several treatment strategies are available (7, 15, 31) . Laboratory tests indicate that bolus delivery of gene therapy is highly promising (27) , but there has been little evaluation in humans, even for basic safety (Phase I trials). Chronic delivery via drug-releasing polymers and infusion pumps has been investigated in multiple trials for nonbrainstem gliomas. Gliadel polymers (Rhône-Poulenc Rorer Pharmaceuticals, Collegeville, PA) have shown efficacy in randomized, double-blind, placebocontrolled trials (5, 35) . Laske et al. (19) used high-flow infusion pumps to deliver a transferrin-linked cholera toxin in 18 patients with recurrent malignant gliomas. Rand et al. (29) used similar pumps in nine patients to deliver a targeted toxin made by linking interleukin-4 to a Pseudomonas exotoxin. Systemic toxicity seemed to be minimal in both trials. This is an area in which more results are expected soon.
We hypothesized that a small-diameter cannula could be implanted into the brainstem for chronic delivery of chemotherapy. The approach is related to a biopsy, but there are obvious, notable differences, including the possibility that the presence of the cannula or the infusion would create inflammatory lesions. Stereotactic techniques are reported to have low morbidity rates, yet risks associated with brainstem biopsies are significant (2, 9, 24, 28) .
High-flow systems, sometimes called "convection-enhanced delivery," are suited for delivering large molecules over centimeter distances (3, 16) and have been used to infuse targeted toxins in monkey (18) and human (19, 29) brain. Nevertheless, we examined a low-flow system, for two reasons. First, although there is information about the effects of high flow rates in brain and nerve, chiefly through studies by Oldfield et al. (3, 10, 18, (21) (22) (23) 30) and by Bruce et al. (6) , there is little information on the effects of chronic pressures from infusions into the brainstem. Edema in the brain can be anticipated and managed by medical therapy (3, 19) or craniotomy (29) . However, there is little relevant information about the management of edema in the brainstem. Second, although drugs diffuse only short distances from low-flow systems and although flow rates of 10 l/d may be suboptimal for certain therapies, low-flow systems mimic the drug distribution pattern of the Gliadel polymer, which has clinical efficacy.
In a stepwise approach to chemotherapy for lesions in tissues with little functional redundancy, it is important to understand the safety of the implant itself and to determine safe baseline infusion rates. The present report demonstrates that the brainstem of a primate can tolerate a small-diameter cannula implant for at least 3 months. Our work provides evidence for the safety of a 3-month infusion of saline and a 1-month infusion of carboplatin at 2.3 g/d. Radiographic signs of toxicity are seen with the infusion of 23 g/d for 2 weeks.
MATERIALS AND METHODS

Animals
Adult male cynomolgus monkeys (Macaca fascicularis) weighing 3 to 5 kg obtained from Biological Research Farms (Houston, TX) were quarantined until found to be in good health by the veterinary staff and then housed in individual cages with free access to a primate pelleted chow and Baltimore city water. Procedures were conducted under Johns Hopkins Animal Care and Use Committee regulations and in accord with federal and state codes.
Supplies
Saline or drug solutions were delivered with 1-ml Duros infusion pumps (Durect Corp., Cupertino, CA) calibrated to deliver solution for 90 days at 10 l/d (0.42 l/h) when fully hydrated at 37°C. Nickel-titanium infusion catheters (outer diameter, 0.3 mm; inner diameter, 0.2 mm) were connected to the pump by 30 cm of silicon tubing. A 3-cm-long open-tipped catheter was used to infuse saline in Animals 1 and 2. A 2.25-cm-long blunt-tipped catheter having 10 pores (0.025 mm in diameter) 0.5 to 3 mm from the distal tip was used to infuse Animals 3 to 5. Pumps, tubing, and catheters were obtained from Durect Corp. Pumps were filled with saline or 5% dextrose solutions of carboplatin (Paraplatin; Bristol-Myers Squibb Co., Princeton, NJ) under sterile conditions by the Hospital Research Pharmacy. Pumps were prepared 24 hours before an implantation and stored at 5°C. They were allowed to warm to 20°C before surgery.
Tubing and catheters were empty on implantation to allow the tissue to seal 24 to 30 hours before the drug solution was infused. Because of the void volume in the tubing and catheter (15.4 l) and the time for the osmotic engine of the pump to hydrate, the initial pulse of the drug reached the brain at a rate of 7 l/d at 30 hours after implantation (EM Gillis, unpublished data). The steady-state rate of 10 l/d was achieved at 150 hours after implantation.
Drug Concentrations
Doses of carboplatin were selected on the basis of estimations of the maximum tolerated dose (MTD) of locally delivered carboplatin in rodents. Toxicity studies with 200-g Fischer rats demonstrated that the MTD of carboplatin delivered into the parietal cortex at 1 l/h for 7 days was 100 g (M Guarnieri, BS Carson Sr, unpublished data). The rodent value was converted to a dose for monkeys through use of equivalent surface area dosage conversion factors. A conversion factor of 0.5 was used to calculate the MTD for a 3.0-kg monkey (11) . Thus, the calculated MTD (cMTD) for the monkey was 0.25 mg carboplatin/kg. Because of the uncertainties associated with these calculations, all doses of carboplatin were delivered for a period of 28 days at 0.42 l/h. Animals 1 and 2 received saline infusions and were observed for signs of toxicity. Animal 3 received approximately 10% of the cMTD. Animals 4 and 5 received a drug dosage approximating the cMTD. The total doses received by Animals 3, 4, and 5 were 82, 850, and 720 g of carboplatin, respectively.
Surgery
After induction of anesthesia, monkeys were placed in a Kopf stereotactic head holder (David Kopf Instruments, Tujunga, CA), and a linear incision was made from the inion to the spinous process of C2. A burr hole was made in the midline on the occipital bone 2.5 cm below the inion. The dura was opened with a No. 11 scalpel blade, and the edges of the dura were coagulated by bipolar cautery. The infusion catheter was then inserted to a pontine target of 1.75 mm anteroposterior, Ϫ12.5 mm dorsoventral, and 0 mm mediolateral in a standard stereotactic atlas (34) . These coordinates were used to determine the resting depth of the catheter tip. We then mapped the linear path of the catheter for these coordinates and inserted the catheter manually through the cerebellum at a 45-degree angle between the catheter and the occipital bone to a depth of approximately 2.25 cm from the surface of the cerebellum.
In Animals 1 and 2, the 3-cm-long catheter was secured to the skull by cyanoacrylate placed in the burr hole. To accommodate independent movement between the skull and the brain, 2.25-cm-long catheters were passed through the skulls of Animals 3 to 5. The tubing was secured to the bone with cyanoacrylate.
The body of the pump was placed in a subcutaneous pocket in the low cervical/high thoracic region and connected to the catheter by silicon tubing. The tubing was looped into the subcutaneous pocket between the pump and the burr hole.
Animals were observed twice daily throughout the experiment for signs of postoperative morbidity, including their gait, interaction with caretakers, grooming habits, and food intake. Pumps were removed at autopsy and opened to verify delivery. Carboplatin solutions remaining in the pump were analyzed by high-performance liquid chromatography. More than 80% of the original drug concentration was preserved at 37°C for 12 weeks.
Radiographic Studies
On postoperative Day 2 to 5, 1-mm slices obtained with a Toshiba Aquilion computed tomographic scanner (Toshiba, Tokyo, Japan) without contrast administration were used to determine placement of the catheter. MRI scans were obtained with a GE Signa 1.5 Cardiac LX scanner (General Electric, Milwaukee, WI): sagittal T1-weighted scans were obtained before and after contrast administration, axial T1-weighted images were obtained before and after contrast (gadolinium) administration, and axial T2-weighted images were obtained approximately 2 weeks after surgery and at intervals thereafter as described in the Results.
Autopsy and Histology
Animals sedated with ketamine and pentobarbital to achieve a lethal dose were perfused with saline and 4% formalin solution. A complete autopsy was performed immediately. Serial coronal sections 5 m thick were taken at 960-m intervals through the brainstem and cerebellum. Adjacent sections were stained for histopathology and analyzed for tissue platinum concentrations. Histology included hematoxylin and eosin (H & E), silver stain for axonal damage, and Perls' stain/diaminobenzidine (DAB) for residual iron. NeuroScience Associates (Knoxville, TN) performed the histopathology. Tissue platinum levels were measured by atomic absorption spectroscopy with a Perkin-Elmer AAnalyst 600 spectrometer (Perkin-Elmer Corp., Norwalk, CT) as described (8, 17) . National Medical Services (Willow Grove, PA) measured the serum and CSF platinum levels. The lower limit of platinum detection was 2 g/L.
RESULTS
Catheter Implantation
Cannulas were inserted through the cerebellum into the roof of the pons with no evidence of perioperative or postoperative morbidity. Animals recovered from surgery rapidly and were active in their cages within 1 hour. They sometimes touched the stitches in their skulls but seemed unaware of the inserted pump. On postoperative Days 1 to 3, the animals underwent a noncontrast computed tomographic head scan to assess catheter placement and rule out the presence of pneumocephalus or epidural, subdural, or intraparenchymal hemorrhage. The scans showed that the infusion catheters were positioned in the midline and revealed no evidence of hemorrhage either along the catheter tract or at the catheter tip. An implanted system is shown in Figure 1 .
Saline Infusion
Animals 1 and 2 were infused with saline for 90 days. We examined whether the catheter would migrate over time or whether the infusion process would provoke an inflammatory response. To address these issues, we performed MRI scans with and without gadolinium at the midpoint and the end of the infusion period (Fig. 2) . The MRI scans showed no evidence of enhancement, hemorrhage, or migration of the catheter tip.
The saline-infused animals showed no signs of neurological deficits or changes in grooming habits, appetite, or activity. Throughout the experiment, the animals remained afebrile and had stable white blood cell counts. Serial complete blood counts and laboratory tests were obtained. There was no difference between baseline results and results during the infusions.
The animals were killed on Day 90, and their brains were removed. On gross inspection of the brainstem, the patholo- gist noted a 2 ϫ 2-mm punctate hemorrhage on the ventral surface of the pons in one of the animals. We were unable to corroborate this finding on the H & E-stained or Perls'/DAB-stained histological sections. The second animal had no evidence of hemorrhage on gross inspection.
There were no histological signs of infection on H & E staining, and the lack of positive staining for ferric iron on the Perls'/DAB stain around the tracts in the pons of both animals suggests an absence of bleeding associated with the indwelling drug delivery catheter (Fig. 3) . On the Perls'/DAB sections through the uvula, however, positive staining was seen in the cerebellum next to the catheter tract in one animal. Bleeding was minimal, and there was no evidence of mass effect on adjacent cerebellar structures or effacement of the fourth ventricle. Both the H & E and Perls'/DAB stains showed glial scarring at the margin of the catheter tract at magnification of ϫ100 (Fig. 3) . Silver stains revealed no evidence of axonal damage.
Carboplatin Infusions
On the basis of the apparent lack of toxicity from the 90-day saline infusions, Animal 3 was infused with 10% of the cMTD. To dilute the neurotoxicity of carboplatin, the calculated amount for 1 week, 0.025 mg/kg, was delivered over a 4-to 5-week period. Behavioral observations, complete blood counts, laboratory tests, radiographic images, and autopsy results were unremarkable throughout the entire 34 days.
Animals 4 and 5 were infused with the cMTD of carboplatin, 0.25 mg/kg. Summaries of the chart notes and MRI studies are given in Table 1 . Complete blood counts and chemistry values were unremarkable throughout the infusion, with one exception. At Week 2, the eosinophil count increased approximately Figure 4A . There was no enhancement with gadolinium. On Day 35, when the cumulative dose was 850 g, the T2-weighted MRI scan was essentially unchanged (image not shown), but a ring of enhancement approximately 0.6 cm in diameter was apparent (Fig. 4B) . The MRI scans for Animal 5 were similar.
The first report of a behavioral change in Animal 4 appeared when the delivered dose of carboplatin reached 486 g on Day 21. The animal was alert and responsive but appeared "slow" and "off-balance" to the veterinary staff. Behavior was then reported as "normal" from Days 22 to 34, at which time the cumulative dose was 824 g. On Day 35, the animal again was noted to be "slow but alert." The animal was killed. The first note of behavioral change in Animal 5 came on Day 26, when the cumulative dose reached 590 g. The animal appeared lethargic and unsteady. These deficits increased during the next 3 days. On Day 30, the animal became ataxic and was killed.
Histopathology of Animal 3 ( Fig. 5A) shows evidence of glial scarring (white arrow) around the catheter space in an H & E-stained serial section through the pons. Adjacent sections (Fig. 5B) stained with Perls'/DAB show the catheter space (white arrow) and necrotic areas (black arrows) extending from the catheter space to a distance approximately 2 mm beyond the catheter. Silver stains revealed no evidence of axonal damage.
Serial sections through the pons of Animals 4 and 5 revealed significant evidence of tissue damage coincident with the hyperintense signal and enhancement observed on MRI. Figure  6A shows an area of necrosis approximately 5 mm in diameter. 
FIGURE 4. MRI scans of Animal 4 at Day 18 (A) and Day 35 (B). A, after a cumulative carboplatin dose of 408 g, hyperintensity is seen on the T2-weighted image. B, after a cumulative dose of 850 g, a ring of enhancement approximately 0.6 cm in diameter is seen.
FIGURE 5. Photomicrographs showing serial cross sections through the pons of a carboplatin-treated (82 g) animal (A, H & E; B, Perls'/DAB stain). A, glial scarring surrounds the cannula space (white arrow). B, necrotic tissue (black arrows) adjacent to and extending approximately 2 mm from the cannula space (white arrow).
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The H & E-stained slice in the section 0.96 mm rostral to this section showed little evidence of damage. However, the silverstained preparation showed significant axonal reaction (Fig.  6B) . The range of tissue damage measured in serial H & E-stained sections is outlined in Figure 7 . The areas of necrosis in serial slices of tissue from Animals 4 and 5 correspond to the location of the catheter tip and the area of enhancement as seen on MRI scans (compare Fig. 4B ). Tissue damage was seen in six to seven adjacent sections in both animals. The focus of necrosis was rostral to the tissue sections containing the maximum tissue concentration of platinum.
Tissue Platinum Levels
Blood and CSF levels of platinum are listed in Table 2 . In Animal 3, the blood concentration at autopsy was undetectable (Ͻ2 g/L). The CSF concentration was 39 g/L. The blood value of platinum in Animal 4 was 4.3 g/L at Day 35. The CSF level was 170 g/L. The platinum blood concentration in Animal 5, which received a total dose of 720 g of carboplatin, was approximately the same: 5.4 g/L; the CSF concentration was almost threefold lower: 64 g/L. We estimate a CSF volume of approximately 100 ml in a 3-kg primate. Thus, the total amounts of platinum in the CSF of Animals 3, 4, and 5 were 3.9, 17, and 6.4 g, respectively.
Tissue platinum concentrations in Animal 3 were below the limits of detection. Concentrations in Animals 4 and 5, measured in coronal sections at 0.96-mm intervals along the long axis of the brainstem, are shown in Figure 7 . Platinum levels greater than 10 ng/mg tissue were found in 12 adjacent sections in Animal 4 and in 13 adjacent sections in Animal 5. The maximum concentrations of platinum were found in sections caudal to the tip of the catheter. Animal 4 had seven adjacent sections with platinum concentrations greater than 20 ng/mg. The maximum amount was 42 ng/mg tissue. Animal 5 had eight adjacent sections with platinum levels exceeding 20 ng/mg tissue and a maximum concentration of 95 ng/mg tissue.
DISCUSSION
The results of this study address several questions about the use of local therapy to treat brainstem tumors and suggest that low-flow infusions are a reasonable approach to lesions in surgically inoperable tissue. First, a 0.3-mm-diameter nickeltitanium infusion catheter can be inserted safely by use of a posterior midline approach to access the roof of the pons of a nonhuman primate. Because humans, unlike these primates, have an occipital sinus, we would advocate a paramedian approach in humans. Other surgical approaches should be investigated, because brainstem tumors present in multiple locations and because the implantation of several catheters might be necessary to compensate for the limited diffusion of low-flow systems.
Evidence of bleeding was seen in the uvula of the cerebellum on the Perls'/DAB-stained sections (Fig. 3) . The hemorrhages were small and clinically insignificant. To minimize "coring" events that result from the use of open-tipped catheters, blunt-tipped catheters were implanted in Animals 3 to 5. However, we have no data to demonstrate that the blunt tip provides an advantage compared with the open-tipped equipment. Cannulas seemed to be biocompatible for at least 90 days. There was no evidence from daily behavioral observations that the monkeys were stressed by the presence of the cannula or the infusion process. Histopathology of sections from saline-infused tissues showed little evidence of inflammation or gliosis. Radiographic and laboratory studies also demonstrate that the monkey can tolerate chronic infusions at 10 l/d. There was no evidence of edema or elevated intracranial pressure. These results demonstrate that the catheter would be suitable for delivering various drugs for several months, e.g., for chemotherapy, targeted toxins, antisense molecules, radiation sensitizers, and immunotherapies that respond to changes in tumor metabolism.
Imaging and serial sectioning showed that the catheter was several millimeters from the ventral surface of the pons. However, it is important to remember that the brainstem is a dynamic structure that changes positions when the head is in a flexed, neutral, or extended position (computed tomographic and MRI scans were obtained with the head in the neutral position). Relative to the brainstem, the fixed catheter will be more ventral when the head is in an extended position. Although movement of the catheter is unlikely to cause symptoms, there is a potential for transient movement. To avoid having a rigid catheter secured to the skull, a 2.25-cm catheter was used in Animals 3 to 5. The full length of the catheter was inside the skull; the silicon tubing was cemented to the bone. Whether this modification provides the intended advantage remains to be determined.
A pharmacologically active dose of carboplatin can be infused into the primate brainstem. There was no evident toxicity from a single trial with one animal infused with 82 g during a period of 34 days. The two animals infused with the cMTD of the drug showed radiographic evidence of tissue reaction at Days 15 and 18 with infused doses of 350 and 408 g, respectively. The behavior of the two animals was normal at the time of the MRI studies, an observation suggesting that radiographic imaging may be a sensitive monitor for drug toxicity. There were notable behavioral anomalies when the cumulative local dose reached 486 g in one animal and 590 g in the second. We are aware of a single comparable reference: Bouvier et al. (4) used 68 catheters during a 10-day period to infuse 8.2 mg of cisplatin (121 g per catheter) into the left frontoparietal lobe of a recurrent malignant glioma patient. There was no evidence of systemic toxicity or neurotoxicity from the treatment.
Assuming that platinum measurements are reliable surrogate assays for carboplatin, data from two animals treated with the cMTD show drug distribution more than 1 cm from the point of infusion (Fig. 7) . The caudal concentration of the drug relative to the insertion site may reflect a bulk flow pattern of the drug or may be driven by edema secondary to tissue damage at the insertion point. Alternatively, the low level of tissue platinum surrounding the insertion area could be an artifact of the tissue damage.
We selected carboplatin specifically for this test, not because we believe it to be the best drug for brainstem lesions, but rather because it is adequately stable at 37°C, measurable by surrogate platinum assays, and widely used in neurooncology. Moreover, a modest amount of information is available on its local toxicity and efficacy against tumor models. Olivi et al. (25) reported a 0.5-mg/kg MTD for interstitial delivery of carboplatin via biodegradable polymers. This dose delivered into the brainstem significantly increased survival in Fischer rats with brainstem inoculations of 9L and F98 tumor cells (8) .
Low-flow systems may be suboptimal for the delivery of certain drugs, and more research is needed to examine the safety of chronic high-flow brainstem infusions. We observed significant morbidity in rats infused at 5 l/h for 7 days (8) but recognize that morbidity in rodent studies depends on the volume and site of the infusion (37) . Recent studies have shown that 4 l of solution can be infused into the rat brainstem at rates of 30 l/h (33) . Further studies are needed to elucidate the pharmacokinetics and long-term effects of local infusions. Brainstem monitoring may be useful in understanding the neurotoxicity. The effects of corticosteroids should be investigated, because patients with brainstem disease frequently receive corticosteroid therapy.
The distribution of carboplatin seen in the present work (Fig. 7) is similar to previously reported values for carboplatin distribution in a normal rodent brainstem (8) and cisplatin in rodent cortex and cerebellum (17) . In both cases, after 1 week of low-flow infusion, the drugs had a symmetrical volume of distribution approximately 1 cm in diameter. The maximum tissue concentration was found at the point of infusion. In the present study, the maximum tissue concentration was found caudal to the point of infusion and in tissue that appeared to be normal by H & E and silver staining histology. Further studies are needed to analyze the distribution of chronically infused drugs in normal and abnormal tissues. Regardless, we suspect that the amount of diffusion seen in Figure 7 would be suboptimal for many brainstem gliomas. Nevertheless, suboptimal treatments, whether surgery, radiation, or chemotherapy, might provide significant survival benefits and should be considered if they do not negatively affect the quality of life. A reasonable option may be to implant several low-flow catheters in diffuse tumors and use targeted toxins. Now that we have established a safe surgical approach, the biocompatibility of the catheter, and flow rate for a primate brainstem infusion, we have a foundation from which to examine therapy at higher flow rates.
Currently, there are many candidate drugs to attack the blood supply, signaling mechanisms, and genomes of malignant cells. Much of this therapy is poorly soluble at the bloodbrain barrier. We suggest that chronic local delivery systems might provide new approaches to brainstem glioma treatment.
argued that there was a transient improvement, but the patient's "remission" was short lived. The approach was not pursued for several reasons. It was difficult technically to deliver drug over a wide area, many catheters and pumps would be needed, each covering only an approximate volume 1 cm in diameter. Secondly, the carboplatin was not a satisfactory medication even for the local treatment of gliomas. We had hoped for a major impact and had not found it. The minimal effect of Gliadel (Rhône-Poulenc Rorer Pharmaceuticals, Collegeville, PA) (2), although statistically significant, supports our original observations. Finally, the boundaries of tumor growth are always poorly defined, so local treatment is likely to be ineffective.
Is it time to reexamine the approach? Only if we have new treatments that require local delivery and distribute more widely. Introduction of novel proteins or genetic material may require local slow infusions to be effective, and there should be no hesitation in using pumps and catheters as required. Acceptable fluid infusion rates are now achievable, and better catheter materials are now available; however, since the toxicology will be different for each agent, more animal experiments will be necessary.
Richard D. Penn Chicago, Illinois
T his is a very well-designed, well-executed, and wellpresented study of infusion into the brainstem of primates. Given the general direction of direct brain infusion for treatment of brain tumors (there are at least five clinical trials of direct infusion into malignant brain tumors), it is a logical extension that preliminary studies begin for untreatable tumors, such as pontine tumors. This article presents a clear, stepwise set of three studies in cynomolgus monkeys. The data are well presented, and the lack of significant toxicity is an important observation in this developing field. The authors' conclusions are conservative, as they must be for such a study.
The only issue that I am concerned about is the infusion rate. The authors used an infusion rate of 0.5 l/h, which corresponds to a rate of 0.0083 l/min. This is more than 1000 times lower than the rates that are now being explored in supratentorial lesions. In their seminal article, Morrison et al.
(1) gave an equation for estimating the steady-state volume of distribution, given known infusion rates and efflux rates: rp ϭ 3͌2qv/4K, where qv is the infusion rate and K is an efflux rate constant. If one uses 0.083 l/min as the infusion rate, and a very conservative value of K (almost 0), the radius of the volume of distribution is less than 1 mm. In other words, this study has shown safety of an infusion rate that is not likely to be clinically useful. The authors are encouraged to continue these studies, but to use higher infusion rates and to include some methodology to document the volume and pattern of distribution. They do not need to use such long infusion times, since the system probably comes into equilibrium within 48 hours. L ocal delivery of therapeutic compounds for brainstem diseases such as diffuse pontine gliomas would be of clinical benefit if efficacy and safety could be demonstrated. The authors describe a method for safely placing a catheter into the brainstem of primates which they used to continuously deliver a chemotherapeutic compound for several weeks' duration. The flow rates and drug concentrations are relatively small but provide an initial approach to investigating chronic drug delivery in an area of the brain not known for its resiliency. Future studies are needed to verify effective volumes of distribution and to compare the rates used in this study with higher infusion rates. High-flow microinfusion with convection-enhanced delivery has already been proven safe in rat and primate brainstem models at infusion rates several hundred times greater than those used in this experimental setup, although for shorter periods of time. The potential to treat brainstem lesions with local therapy is an appealing one, and further studies to advance this strategy are eagerly awaited.
Dennis Groothuis
Jeffrey N. Bruce New York, New York
